14 jun 2024

Tempus

Tempus es una empresa tecnológica que promueve la medicina de precisión a través de conocimientos basados en datos. La plataforma de la empresa utiliza inteligencia artificial y aprendizaje automático para analizar datos clínicos y moleculares, ayudando a investigadores y médicos a tomar decisiones más informadas en la atención al paciente. El trabajo pionero de Tempus en el análisis de datos y la genómica está reconfigurando el enfoque del diagnóstico y el tratamiento de las enfermedades, especialmente el cáncer.

Gráfico NewsHeat

  • Semana
  • Mes
  • Año
  • Noticias de prensa
  • Noticias corporativas
Haga clic para desbloquear el gráfico

Los datos del gráfico anterior se basan en datos derivados de nuestro modelo de cálculo XP patentado y pueden modificarse, ajustarse y actualizarse sin previo aviso.

Valoración de empresas

  • Valoración
  • Precio de las acciones
  • Financiación acumulada

Los datos de los cuadros y gráficos se basan en datos de fuentes públicas y, aunque hacemos todo lo posible por recopilarlos, es posible que no coincidan con los datos reales del emisor.

Ronda de financiación
Importe de la financiación
Valoración Post-Money
Precio de las acciones
Growth Capital20 oct, 2022
***
***
***
Series G10 dic, 2020
***
***
***
Series G13 mar, 2020
***
***
***
Series F30 may, 2019
***
***
***
Series E29 ago, 2018
***
***
***
Series D20 mar, 2018
***
***
***
Series C25 sept, 2017
***
***
***
Series B17 abr, 2017
***
***
***
Series B22 nov, 2016
***
***
***
Series B20 jun, 2016
***
***
***
Series A21 sept, 2015
***
***
***

*** - Para ver los datos, conéctese a su cuenta o cree una nueva.

Noticias relacionadas con Tempus177

Filtrar por
Ordenar por
Tempus
ene 3, 2025 Mostrar en el gráfico

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions - Tempus

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of Ca...

Tempushttps://www.tempus.com/news/tempus-now-an-in-network-provider-for-blue-cross-blue-shield-illinois-blue-shield-california-and-more/
Tempus
dic 13, 2024 Mostrar en el gráfico

Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas. “Presenting our l...

Tempushttps://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium/
Tempus
nov 29, 2024 Mostrar en el gráfico

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York...

Tempushttps://www.tempus.com/news/pr/tempus-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference/
Tempus
nov 15, 2024 Mostrar en el gráfico

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR® - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of...

Tempushttps://www.tempus.com/news/pr/tempus-molecular-profiling-integration-now-available-through-flatirons-oncoemr/
Tempus
nov 15, 2024 Mostrar en el gráfico

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with adva...

Tempushttps://www.tempus.com/news/pr/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in-advanced-cancer-care/
Ver más (172)

Inversores8

New Enterprise AssociatesNew Enterprise Associates
RevolutionRevolution
T. Rowe PriceT. Rowe Price
Baillie GiffordBaillie Gifford
Novo HoldingsNovo Holdings
Franklin TempletonFranklin Templeton
GoogleGoogle
Franklin Templeton InvestmentsFranklin Templeton Investments

Tempus Twitter